Following SMC collaboration with NICE on TA1056: molnupiravir for treating COVID-19:
molnupiravir (Lagevrio®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness.
SMC restriction: as an option for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test, only if:
- they have 1 or more risk factors for progression to severe COVID-19 (as defined in section 5 of NICE’s technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19) and
- both nirmatrelvir plus ritonavir and sotrovimab are contraindicated or unsuitable.
Full details of the assessment and recommendations can be found at Overview | Molnupiravir for treating COVID-19 | Guidance | NICE.
Download detailed advice237KB (PDF)
Medicine details
- Medicine name:
- molnupiravir (Lagevrio)
- SMC ID:
- SMC2556
- Indication:
Treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness.
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Infections
- Submission type
- Collaboration
- Status
- Restricted
- Date advice published
- 16 April 2025